FR2757390A1 - Cosmetic compositions containing Barringtonia extract - Google Patents

Abstract

Novel cosmetic compositions contain an extract (I) of the plant Barringtonia, especially Barringtonia asiatica or Barringtonia racemosa, together with a cosmetic carrier. The cosmetic or dermatological use of (I) is also claimed. Barringtonia plants are members of the Lecythidaceae family and are found in New Caledonia.

Description

The invention relates to uses of an extract of the plant
Barringtonia, in the cosmetic and pharmaceutical fields, especially dermatological.

 It relates more specifically to uses as a cosmetic agent of an extract of this plant.

 The Barringtonia plant, particularly the species Barringtonia asiatica and Barringtonia racemosa are plants of the family Lecythidaceae found especially in New Caledonia.

 The systematic tests carried out by the inventors made it possible to demonstrate a certain number of surprising enzymatic actions of the extracts of this plant, in particular the actions of inhibition of several enzymes, in particular elastase, phospholipase A2, lipoxygenase, tyrosinase and 3 ', 5'-AMPc-phosphodiesterase, which made it possible to envisage its use in cosmetic and pharmaceutical products, especially dermatological products.

 Elastase, the enzyme that degrades elastin, is present in cells, particularly in the dermal cells (fibroblasts) and, to a lesser extent, in the cells of the epidermis (keratinocytes). The amount and activity of elastase has been observed to increase during the skin aging process, both intrinsically and artificially. By a degradation of the elastin fibers, the action of elastasc results in a loss of skin elasticity, loosening of the skin and the appearance of wrinkles.

 Phospholipase A2 (PLA2) is an enzyme produced by cells at the membrane level. It predominates in cells related to inflammation phenomena, such as mast cells. By its action, it releases arachidonic acid bound to membrane phospholipids. This acid then metabolizes to various lipid mediators of inflammation and allergy, such as Icucotrienes and Prostaglandins.

 5'-lipoxygenasc, hereinafter referred to as "lipoxygenase", is, like PLA2, a multimeric enzyme. It intervenes in the "cascade of inflammation" downstream of the release of arachidonic acid by PLA2, in the conversion of this acid into Icucotrienes, mediators of inflammation.

 3 ', 5'-cAMP phosphodic esterase, hereinafter referred to as "phospho-diestcrase" or "PDE", is the enzyme which transforms cAMP, the second messenger involved in the control of cellular metabolism, into inactive AMP. Inhibition of PDE by an inhibitory agent consequently makes it possible to maintain a high intracellular level of cAMP, which in particular has the effect of activating protein kinases A, and by this process makes it possible to promote the degradation of lipids. .

 In addition, it is also known that cAMP is involved in counteracting certain inflammatory processes (Hitchcock, J. Immunol (1977) 188 557).

Also, it has been reported that phosphodiesterase increases with age (S.K. Puri and L. Volicer, Mechanisms of Aging and Dev. (1981) 239). As a result, its inhibition will help fight the effects of aging, particularly at the skin level.

 Tyrosinase is the key enzyme in the synthesis of melanin and thus the metabolism of cutaneous pigmentation. In cosmetics, its inhibition, by appropriate agents, find applications in the local treatment of cutaneous hyperpigmentations, such as the pigmentary spots of senescence.

 Thus, it has been demonstrated by the inventors that, thanks to their inhibitory action on the aforementioned enzymes, the extracts of the Barringtonia plant, in particular Barringtonia asiatica, were of great interest in cosmetics and therapeutics.

Indeed, by the discovery of the activity of the extracts of the plant
Barringtonia, in particular Barringtonia asiatica, inhibiting the action of enzymes,
The invention provides various solutions in the field of cosmetics and therapeutics, especially dermatology. As regards the inhibition of elastase, the compositions according to the invention are opposed to the degradation of elastin fibers and, as a result, these compositions maintain the biomechanical qualities of the skin, in particular its qualities of elastin. elasticity in the dermis, and make it possible to combat the release of the skin and the appearance of wrinkles. With regard to the inhibition of phospholipase A2 on the one hand and lipoxygenase on the other hand, the compositions according to the invention thus act doubly in the process of forming the mediators of cutaneous allergy and inflammation. , limiting or blocking this process.

 Inhibition of phosphodiesterase (PDE) leads to a slimming, anti-inflammatory and anti-aging action of the compositions of the invention. Inhibition of tyrosinase gives them a depigmenting effect on the skin.

 Other advantages of the invention appear from the description and examples which follow.

Thus, according to one of its essential characteristics, the invention relates to cosmetic compositions containing an extract of the plant
Barringtonia in the presence of a cosmetically acceptable vehicle.

 Advantageously, an extract of the plant Barringtonia asiatica or racemosa will be chosen.

 It is essentially the leaves and / or the fruits that are interesting for the preparation of the extracts of the invention.

 The extract is advantageously obtained by maceration of the plant part in a solvent or a mixture of solvents, followed by filtration. The solvent of the obtained solution can be evaporated if necessary to obtain the dry extract.

 Preferably, the evaporation will be carried out under reduced pressure.

As solvents advantageously used, mention will be made of:
- water
chlorinated solvents, in particular dichloromethane
ethers, such as ethyl or diisopropyl ether
- acetone
esters C2 to C8 such as ethyl acetate and butyl acetate
- C1 to C6 alcohols, such as methanol, ethanol and isopropanol
C2 to C6 polyols, such as propylene glycol or glycerol.

 The extract of the plant can also be obtained by the technique known as supercritical carbon dioxide extraction.

 According to an advantageous embodiment, this composition comprises from 0.001 to 10% by weight and in particular from 0.02 to 1% by weight of dry extract of the plant relative to the total weight of the final composition.

 Furthermore, the tests carried out by the inventors have clearly shown that not only the extraction yield was related to the nature of the solvent used but also the enzymatic activity of the extract. The examples in the appendix clearly show the effect of the choice of solvent on the enzymatic activity of the extract.

 The compositions according to the invention can be formulated in any form acceptable for use in cosmetology. It may, in particular, be a composition in a form suitable for topical application, in particular in the form of a cream or a gel, in particular a cream or a gel for the face, hands, bust or body.

 According to another aspect, the invention relates to the use of the plant extract as a cosmetic agent, said agent being incorporated in a cosmetic composition as defined above.

 This cosmetic agent will be used in particular in all applications where it is sought, in particular, to inhibit the action of elastase and / or phospholipase A2 and / or lipoxygenase, and / or phosphodiesterase and / or or tyrosinase.

 They will also be used to combat the effects of aging on the skin, in particular by preserving or improving the biomechanical qualities of the skin, in particular its elasticity, by retaining the appearance of wrinkles or decreasing their depth and by improving cutaneous firmness. .

 They will still be used for the care of sensitive skin, including by reducing or eliminating the phenomena of irritation, inflammation or allergies that are generally reflected in the skin by redness, burning or stinging sensations.

 They can also cutter used to obtain a thinning of different parts of the body, especially hips. They may also be destined to reduce or eliminate skin pigmentary spots.

 Thus, the cosmetic compositions of the invention will be used in particular for all cosmetic applications where it is sought to inhibit the activity of the aforementioned enzymes.

 Thus, according to another aspect, the invention relates to cosmetic compositions intended for the care of the skin, in particular for combating the effects of skin aging or inflammation phenomena.

 They are also interesting for their slimming action or their depigmenting action.

 As has been seen previously, the effectiveness of the previously described cosmetic compositions could be correlated with a number of enzymatic activities. The demonstration of these enzymatic activities made it possible to envisage also the use of the extracts defined above for the preparation of pharmaceutical compositions, especially dermatological compositions in which such activities are desired. The tests carried out by the inventors of the present invention have confirmed the effectiveness of these pharmaceutical compositions.

 Thus, inhibition of phospholipase A2 and inhibition of 5'lipoxygenase have been correlated with efficacy in the prevention and treatment of inflammation phenomena.

 The inhibition of elastase could be correlated with anti-aging activity conferred on the skin by the compositions of the invention.

 Inhibition of tyrosinase could be correlated with an action in the local treatment of hyperpigmentation of the skin.

 Inhibition of PDE results in maintaining a high level of intracellular cAMP. This leads to various effects on the skin, in particular slimming, anti-aging and anti-inflammatory effects.

 Thus, according to another characteristic, the invention also relates to the use of an extract of the Barringtonia plant for the preparation of a pharmaceutical composition, especially a dermatological composition, intended for the treatment of the effects of intrinsic or actinic aging of the skin, prevention or treatment of cutaneous manifestations of allergies and inflammations, reduction of subcutaneous fat overloads, treatment of cutaneous tasks to reduce or eliminate them, said extract being incorporated in a pharmaceutically acceptable vehicle.

 For these different applications, the pharmaceutical composition advantageously has an inhibitory activity of elastase and / or phospholipase An and / or lipoxygenase and / or phosphodiesterase and / or tyrosinase.

According to a variant, the invention relates to the use of an extract of
Barringtonia for the preparation of a pharmaceutical composition, especially dermatological for the treatment and prevention of allergic manifestations, especially skin allergy.

 This type of application is directly related to the inhibition of lipid mediators of inflammation.

 In all the applications of the pharmaceutical field, especially dermatological, the compositions used are preferably compositions for topical application intended to be applied to the skin. Moreover, the extracts of the plant used for their preparation are obtained in the same way as the extracts used in the cosmetic field, from the same plant parts and are introduced into a pharmaceutically acceptable vehicle, especially dermatologically acceptable at concentrations between 0.001% and 10% by weight, and in particular between 0.02% and 1% by weight, of dry extract of said plant or part of a plant.

 As in the case of cosmetic applications, the extraction solvent will be chosen according to the type of enzymatic activity that will be preferred in the action of the pharmaceutical composition.

 The following examples are given purely by way of illustration of the invention.

Unless otherwise indicated, the proportions given in the examples of compositions are expressed in percentage by weight.
Example 1
Preparation of an extract according to the invention
1 g of leaves of the plant Barringtonia asiatica previously dried and ground is introduced into 200 ml of solvent. The suspcnsion is left at room temperature with moderate stirring for 4 hours. The mixture is then filtered and the solvent of the filtrate thus obtained is evaporated off under reduced pressure.

The dry extract is then recovered. To prepare the compositions according to the invention, it is possible to use either the solution of plant extract, optionally concentrated, in the extraction solvent, or the dry extract.

 Extracts were made using two different solvents: water and methanol.

Example 2
Demonstration of the inhibitory activity of the extracts on different enzymes 2.1 Extract used
The enzymatic inhibition tests being conducted in an aqueous medium, it is necessary to use water-miscible extraction solvents.

 Thus, proceeding as described in Example 1, three different extracts were made using not the leaves but the fruits of Barringtonia asiatica, with respectively water, methanol and DMSO. The concentration of these extracts is then adjusted to 0.5% in dry plant extract, either by addition or by evaporation of the extraction solvent.

 All tests described below have been performed in triplicate. The reported values are arithmetic means.

2.2. Inhibition of elastase a) Principle of the test:
Techniques for demonstrating elastase inhibition have been described by various authors (BAUMSTARK, JS et al., Biochim Biophys Acta (1963), 77, 676, BIETH, B. et al., Biochem. Mcd, (1974), 350, C. FRANCK,
I. BYRJALSEN, Biol. Chem. Hoppe Seyler, (1988) 369 (8) 677-82).

 The active principle is as follows: a substrate is placed in the presence of elastase in an aqueous medium, then, after incubation, a measurement of the reaction products is carried out.

 In this case, the substrate is N-succinyl- (Ala) 3 -paranitroanilide, available from the company Sigma (Ref .: S 4760) in solution at 0.5 mg / ml in a Tris-HCl 0 buffer, 2 M at pH 8.8. The elastase added to the reaction medium releases para-nitroaniline and the peptide residue. The evolution of the reaction is observed with the spectrophotometer Uvikon 941 (!) (Kontron S.A.) at the wavelength λ of 379 nm.

The composition of the reaction medium is as follows
substrate solution (0.5 mg / ml buffer): 200, ul
Tris-HC1 buffer: 600, ul
- extraction solvent: 100 jtl
The extraction solvent contains or not the effector, that is to say the extract of the plant Barringtonia, at the concentration of 0.5% by weight, depending on whether it is the test with effector, or test without effector (basal activity of the enzyme).

 To these 900 μl of reaction medium, 100 μl of the enzyme solution at a rate of 35 U / ml are immediately added to the Tris-HCl buffer.

The cinctic of the para-nitroaniline release is then measured by the absorption of a monochromatic light of wavelength 379 by means of the spectrophotometer, which makes it possible to calculate the percentage of inhibition 1E according to the formula - dcssous below:
lE = AAbB / min - AAbE / min x 100 bAbB / min in which hAbB / min is the absorbance difference per minute of the reaction medium for the basal activity, and hAbE / min, the absorbance difference of the reaction medium for the test with effector. The absorbance values taken into account are those corresponding to the linear period of the evolution of the absorbance as a function of time.

 The results are shown in Table I below.

2.3. Inhibition of phospholipase A2
According to the test principle (UTHE, JF and MAGEE, WL, Can.

Biochem. (1971), 49, 776; DENNIS, EA, J. Lipids Res., (1973), 14, 152),
The enzyme is placed in the presence of a phospholipid. This is then converted into lysolecithin with release of a fatty acid, insoluble in the reaction medium.

This reaction can therefore be suvie by turbidimetry using a spectrophotometer, using for example the wavelength of 360 nm.

 The composition of the reaction medium is indicated below. All solutions are made in distilled water.

14 mM solution of L-phosphatidylcholine dimyristoyl (substrate): 600 μl - 0.67 M sodium chloride solution: 150 M1 - 66 mM calcium chloride solution: 200 μl - distilled water: 850 μl solvent without or with effector at 0.5 to 100 l 100, ul
To this medium is added immediately 100 l of enzyme solution in distilled water at a concentration of 96 U / ml.

 As in the case of elastase inhibition, the reaction kinetics are monitored by means of a Uvikon941t spectrophotometer at the wavelength of 360 nm.

The percentage inhibition of Ip phospholipase A2 is determined by calculation according to a formula similar to that of the inhibition of elastase
# AbB / Mn # ABE / min
Ip = x 100
# AbB / mn in which hAbB and AAbE have the same meaning as before.

 The results are shown in Table I below.

2.4. Inhibition of 5'-lipoxvgenase
As has been stated above, lipoxygenase is involved in the formation of mediators of inflammation, particularly leukotrienes, from arachidonic acid.

 In the test to demonstrate the inhibition of this enzyme (C.W.

Taylor, HR Morris, Brit. Med. Bull. (1989) 39 219-222; J. Magee, Methods of
Enzymatic Analysis, HU Bergmayer Ed., (1965) p. 411-4, Academic Press, NY), linoleic acid is used as substrate which is converted in the presence of the enzyme to 5-hydroperoxy-6,8,1 1,14-eicosatetraenoic acid (5
HPETE).

Composition of the reaction medium: linoleic acid (substrate), 0.5 mM solution: 2000, 0.2 M borate buffer at pH 9: 950 l solvent, with or without 0.5% effector: 100 M1 in the borate buffer
To prepare the above linoleic acid solution, partial salification of the linoleic acid in methanol in the presence of sodium hydroxide is carried out beforehand, and then it is introduced into the borate buffer.

 100 l of solution of the enzyme 5'lipoxygénase in borate buffer at the concentration of 10 U / ml are then added extemporaneously.

 As in the previous tests, the absorbance of the media as a function of time is measured, and the percentage of IL inhibition of the 5'-lipoxygenase is calculated for the linear part of the evolution of the absorbance.

 The results are shown in Table I below.

2.5 Inhibition of phosphodiesterase (PDE)
The principle of this test is based on the hydrolysis of the 3 ', 5'-adenosine monophosphate cylcique (AMPe) adenosinc monophosphatc (AMP). AMP formation is measured by HPLC analysis.

 The composition of the reaction medium is indicated below. The reagent solutions are made in 0.05 M Tris-HCl buffer at pH 7.5.

cAMP solution (substrate) at 0.25% in buffer 80, ul-solvent, with or without a 0.5% effector 80 Fl-buffer Tris-HCl 480 Fl
To this medium, 160 μl of PDE at 0.5 U / ml are immediately added to the Tris-HCl buffer.

 At time t = 5 minutes, the amount of AMP formed is calculated by calculating the integration area of the AMP peak on the chromatogram supplied by the HPLC apparatus (KONTION S.A.).

We can then estimate the inhibition rate of the PDE IA by the effector according to the formula:
SAMPb - SAMPe IA = x 100
SAMPb
wherein SAMPb represents the peak integration area of AMP for the basal activity of the enzyme (without effect) and SAMPe represents the integration area of the peak of the MP for the activity of the enzyme in the presence of the effector.

 The results obtained are shown in Table I below.

2 6 Inhibition of tvrosinase
The principle of this test is based on the formation of dopachrome from L-tyrosine by the action of tyrosinase.

It is reported that L-tyrosine, in the presence of tyrosinase and oxygen, oxidizes to L-DOPA, which in turn oxidizes, again by the action of tyrosinase, into dopaquinone. It then cyclizes to cyclodopa, which oxidizes to dopachrome, a precursor of melanins, and absorbs light at a wavelength of 480 nm.

<Tb>

<SEP> tyrosinase <SEP> tyrosinase
<tb> L-tyrosine <SEP> b <SEP><SEP> L-DOPA <SEP> b <SEP><SEP> dopachrome
<tb><SEP> (A <SEP> = <SEP> 480 <SEP> nm)
<Tb>
melanins
The formation of dopachrome can therefore be followed spectrophotometrically.

 For this method, reference may be made in particular to the publications of S. H. Pomcrantz. Arch. Biochem. Biophys. (1974) 160 73-82, or J. Barber, J. Invest. Dcrmatol. (1984) 83145-149.

 The composition of the reaction medium is indicated below. The solutions of the reagents are made in 0.02 M phosphate buffer at pH 6.9.

solution of L-tyrosine (1 substrate) at 1 mM in buffer 333 F1-solution of L-DOPA (2nd substrate) at 1 mM in buffer 333 Fl-solvent, without or with effector at 0.5% 333 Fl
To this reaction medium, 33 Cll of tyrosinase solution at a concentration of 2400 U / ml are added immediately to the phosphate buffer.

The kinetics of the dopachrome formation are then measured by the absorption of a monochromatic light with a wavelength of 480 nm using a Uvikon 941 spectrophotometer (KONTION SA), which makes it possible to calculate, for the linear part of the evolution of the absorbance as a function of time, the percentage of IT inhibition of tyrosinase according to the formula below:
AbB / mn - A AbE / mn
1T = AAbB / min X 100
in which hAbB / min is the difference in absorbance per minute of the reaction medium for the basal activity of the enzyme (without effector), and hAbE / min, the absorbance difference of the reaction medium for the effector test.

 The results are shown in Table I below.

TABLE I
Enzymatic inhibition rate by the extracts of the invention

<tb><SEP> Extracts
<tb><SEP> E <SEP> water <SEP> E <SEP> methanol <SEP> E <SEP> DMSO
<tb><SEP> 1E <SEP> (elastase) <SEP> 67 <SEP> 67 <SEP> 2
<tb><SEP> tP <SEP> (PLA2) <SEP> 35 <SEP> 42 <SEP> 48
<tb> 1L <SEP> (lipoxygenase) <SEP> 10 <SEP> 1 <SEP> 93
<tb><SEP> 1T <SEP> (tyrosinase) <SEP> 73
<tb><SEP> 1A <SEP> (PDE) <SEP> 92 <SEP> 87 <SEP> 85
<Tb>
E water: aqueous extract, 0.5%
E methanol: methanol extract, 0.5%
E DMSO: 0.5% DMSO extract
The results appearing in Table i above demonstrate the interest of the extracts according to the invention, in the fields of cosmetics and pharmacy, especially in dermatology, as soon as it is a question of blocking, of diminishing the importance or to regulate the action of certain enzymes.

 More specifically, it is clear that each of the five enzymes tested is significantly inhibited by at least one of the extracts tested.

The action of Barringtonia asiatica extracts is particularly important on the inhibition of phosphodiesterase and elastase. However,
The aqueous extract is also very active on the inhibition of tyrosinase, and the DMSO extract is very active on that of lipoxygenase.

 As a result, the Barringtonia extracts can be advantageously used for the various applications mentioned above resulting from the inhibition of the enzymes concerned.

Example 3
Anti-wrinkle cosmetic gel - Dry extract of Example 1, methanol fraction 0.05 g - Carbomer 0.3 g - Glycerin 3.0 g - Tetrasodium tetra 0.05 g - Hammamelis floral water 3.00 g - Polymethyl methacrylate. 1.00 g - Perfumes, preservatives, dye, neutralizer qs - Distilled water qs 100 g
This gel has an anti-wrinkle and soothing effect.

Exemole 4
Anti-wrinkle cream for the face - Dry extract according to Example 1, aqueous fraction 0.5 g - Glyceryl stearate + PEG 100 stearate 5.0 g - Cetyl alcohol 1.0 - Stearyl alcohol 1.0 - Wax of abscillc 1,50 - Squalane 3,0 - Hydrogenated polyisobutene 4,0 - Cetearyl octanoate 1,50 - Tricaprylate / glycerol caprate 3,0 - Dimethicone 1,0 - Gum xanthane 0,2 - Carbomer. 0,15 - Glycerin 2,0 - Neutralizer, preservative, perfumes, dyes qs - Water qs 100
Example 5
Cream for sensitive skin - Barringtonia asiatica dry fruit extract prepared according to the method of Example 1, methanolic fraction 0.2 g - Methylglucose sesquistearate 3.0 - Beeswax 3.0 - Behen alcohol 3.0 - Octanoate octyl 5, 0 - Fluid mineral oil 7,5 - Cetostearyl octanoate 5,0 - Glycerin 3,0 - Xanthan gum 0,50 - Perfumes 0,30 - Preservative, dyes qs - Water qs 100
<RTI
The cream thus obtained is applied once or twice a day to the parts of the body to be treated, such as the hips, for a cure of one to three weeks.

Example 7
Depigmenting gel
Dry extract according to Example 1.

Water fraction 1 g
Phosphate buffer 49g
4% Carbopol 9408 Gel Excipient
neutralized, with preservatives qs 100 g
This gel is used in local application on hyperpigmented areas of the skin. It is particularly intended to treat senescence pigment spots on the hands, to mitigate or remove them.

Example 8
Depigmenting gel
Aqueous extract solution according to Example 1,
at 5% in distilled water 4g
Ripe bark extract 0.35 g
Ascorbic acid 0.6 g Carbopol 940 # 2g
Water + preservatives qs 100g
This gel is recommended, at the beginning of treatment, to treat skin spots such as senescence spots locally.

Claims (21)

 1. Cosmetic composition, characterized in that it contains an extract of the Barringtonia plant in the presence of a cosmetically acceptable vehicle.  2. Cosmetic composition according to claim 1, characterized in that the Barringtonia plant is selected from the species Barringtonia asiatica and Barringtonia racemosa.  3. Cosmetic composition according to one of claims 1 or 2, characterized in that said extract of said plant is an extract of leaf and / or fruit.  4. Cosmetic composition according to one of claims 1 to 3, characterized in that said extract is obtained by maceration of said plant in a solvent or a mixture of solvents, followed by filtration and, if necessary, evaporation solvent.  5. Cosmetic composition according to claim 4, characterized in that said solvent is selected from the group consisting of water, chlorinated solvents, especially dichloromethane, ethers such as ethyl or diisopropyl ether, acetone, esters. C 2 to C 6 alcohols, such as ethyl acetate and butyl acetate, C 1 to C 6 alcohols, such as methanol, ethanol and isopropanol, C 2 to C 6 polyols, such as propylene glycol and glycerol, and mixtures thereof.  6. Cosmetic composition according to one of claims 1 to 3, characterized in that said extract is obtained by supercritical carbon dioxide extraction.  Cosmetic composition according to one of the preceding claims, characterized in that it comprises from 0.001% to 10% by weight, and in particular from 0.02% to 1% by weight, of extract of said plant. .  8. Cosmetic composition according to one of claims 1 to 7, characterized in that it is in any form suitable for topical application, in particular in the form of a cream or a gel, in particular a cream or gel for the face, hands, bust or body.  9. Use of an extract of the Barringtonia plant as a cosmetic agent, said agent being incorporated into a cosmetic composition as defined in one of claims 1 to 8.  10. Use according to claim 9, characterized in that said cosmetic agent contained in said composition has an inhibitory action of elastase and / or phospholipase A2 and / or lipoxygenase and / or phosphodiesterase and / or tyrosinase.  11. Use according to one of claims 9 or 10, characterized in that said composition is intended to combat the effects of aging on the skin, in particular by preserving or improving the biomechanical qualities of the skin, in particular its elasticity, in particular. delaying the appearance of wrinkles or decreasing their depth, and improving the skin's fcrmeté.  12. Use according to one of claims 9 to 11, characterized in that said composition is intended for the care of sensitive skin, including by reducing or eliminating the phenomena of irritation, inflammation or allergy, which result usually on the skin by redness, burning or tingling sensation.  13. Use according to one of claims 9 to 12, characterized in that said composition is for the thinning of the various parts of the body, in particular hips.  14. Use according to one of claims 9 or 10, characterized in that said composition is intended to reduce or remove skin pigment spots.  15. Use of an extract of the Barringtonia plant for the preparation of a pharmaceutical composition, especially a dermatological composition, intended for the treatment of the effects of intrinsic or actinic irritation of the skin, for the prevention or treatment of cutaneous manifestations of allergies and allergies. inflammation, the reduction of subcutaneous fat overload, the treatment of cutaneous tasks to reduce or eliminate them, said extract being incorporated in a pharmaceutically acceptable vehicle.  16. Use according to claim 15, characterized in that said plant extract is an extract of Barringtonia asiatica or racimosa.  17. Use according to one of claims 15 or 16, characterized in that said plant extract is an extract of fuille and / or fruit.  18. Use according to one of claims 15 to 17, characterized in that the composition has Irone inhibitric activity of elastase and / or phospholipase As and / or lipoxygenase and / or phosphodiesterase and / or tyrosinase.  19. Use according to one of claims 15 to 18, characterized in that said composition contains from 0.001% to 10% by weight, and in particular from 0.02% to 1% by weight, of dry extract of said plant .  20. Use according to one of claims 15 to 19, characterized in that said composition is formulated for topical application to the skin.  21. Use according to one of claims 15 to 20, characterized in that said extract is obtained according to a method defined in one of claims 4 to 6.